Nicole Hadas

Insider profile

Currently holds positions in Keryx Biopharmaceuticals Inc and Akebia Therapeutics Inc

Performance

Overall performance
3.5
Performance over holding periods
3.5
30 days 90 days 120 days
Average return 18% 8.2% 15.1%
Success rate 92% 68% 82%
Transactions
15 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
President, Secretary Keryx Biopharmaceuticals Inc Dec. 12, 2018 -
Senior Vice President, Chief Legal Officer, Corporate Secretary Akebia Therapeutics Inc Jan. 1, 2013 -
Nicole Hadas's trades of Akebia Therapeutics Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Planned sale
Price
402.56
Quantity 54,166 +33.2%
Value US$2,128,615
Transaction date
Proposed sale
Price
444.88
Quantity 88,711
Value US$1,958,059
Transaction date
Proposed sale
Price
1.58
Quantity 5,974
Value US$9,417
Transaction date
Planned sale
Price
1.52
Quantity 7,411 -1.1%
Value US$11,265
Transaction date
Proposed sale
Price
1.52
Quantity 7,411
Value US$11,245
Transaction date
Proposed sale
Price
1.22
Quantity 63,186
Value US$77,270
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2024-05-14 2024-05-13
PlS Planned sale
54,166 +33.2%
402.56
US$2,128,615 		54,166 +33.2% 402.56 US$2,128,615
2024-05-13 2024-05-13
PrS Proposed sale
88,711
444.88
US$1,958,059 		88,711 444.88 US$1,958,059
2024-03-01 2024-02-29
S Sale
86,397 +26.0%
429.42
US$4,318,526 		86,397 +26.0% 429.42 US$4,318,526
2024-02-29 2024-02-29
PrS Proposed sale
5,974
1.58
US$9,417 		5,974 1.58 US$9,417
2024-02-29 2024-02-27
PlS Planned sale
7,411 -1.1%
1.52
US$11,265 		7,411 -1.1% 1.52 US$11,265
2024-02-27 2024-02-27
PrS Proposed sale
7,411
1.52
US$11,245 		7,411 1.52 US$11,245
2023-05-25 2023-05-25
PrS Proposed sale
63,186
1.22
US$77,270 		63,186 1.22 US$77,270
2023-05-25 2023-05-25
S Sale
63,186 -10.8%
1.22
US$77,270 		63,186 -10.8% 1.22 US$77,270
2023-03-03 2023-03-01
S Sale
1,088 -0.4%
0.88
US$955 		1,088 -0.4% 0.88 US$955
2023-03-03 2023-03-01
S Sale
6,613 -2.2%
0.88
US$5,803 		6,613 -2.2% 0.88 US$5,803
2023-03-03 2023-03-01
S Sale
5,333 -1.8%
0.88
US$4,680 		5,333 -1.8% 0.88 US$4,680
2023-03-01 2023-02-27
PlS Planned sale
6,677 -2.2%
0.81
US$5,430 		6,677 -2.2% 0.81 US$5,430
2022-03-02 2022-03-01
PlS Planned sale
1,078 -0.4%
2.17
US$2,340 		1,078 -0.4% 2.17 US$2,340
2022-03-02 2022-03-01
S Sale
6,556 -2.1%
2.17
US$14,231 		6,556 -2.1% 2.17 US$14,231
2022-03-02 2022-03-01
S Sale
6,873 -2.2%
2.17
US$14,919 		6,873 -2.2% 2.17 US$14,919
2022-03-02 2022-02-28
S Sale
6,555 -2.4%
2.15
US$14,125 		6,555 -2.4% 2.15 US$14,125
2021-04-01 2021-04-01
S Sale
1,060 -0.4%
3.40
US$3,604 		1,060 -0.4% 3.40 US$3,604
2021-03-02 2021-03-01
S Sale
7,976 -2.9%
3.40
US$27,087 		7,976 -2.9% 3.40 US$27,087
2021-03-02 2021-03-01
S Sale
6,309 -2.3%
3.40
US$21,426 		6,309 -2.3% 3.40 US$21,426
2020-03-02 2020-02-28
S Sale
7,050 -3.2%
8.70
US$61,335 		7,050 -3.2% 8.70 US$61,335
2017-10-04 2017-10-02
PlS Planned sale
1,553 -1.4%
19.64
US$30,501 		1,553 -1.4% 19.64 US$30,501
2017-07-06 2017-07-03
PlS Planned sale
1,554 -1.4%
14.26
US$22,156 		1,554 -1.4% 14.26 US$22,156
2017-04-04 2017-04-03
S Sale
1,556 -1.4%
9.18
US$14,280 		1,556 -1.4% 9.18 US$14,280
2017-01-03 2017-01-01
PlS Planned sale
1,810 -2.1%
10.49
US$18,988 		1,810 -2.1% 10.49 US$18,988
2016-10-04 2016-10-01
S Sale
1,556 -1.8%
8.95
US$13,934 		1,556 -1.8% 8.95 US$13,934
2016-07-06 2016-07-05
PlS Planned sale
1,557 -1.8%
7.47
US$11,625 		1,557 -1.8% 7.47 US$11,625
2016-04-05 2016-04-04
S Sale
1,556 -1.8%
9.41
US$14,642 		1,556 -1.8% 9.41 US$14,642
2016-01-06 2016-01-04
PlS Planned sale
1,811 -2.7%
12.28
US$22,239 		1,811 -2.7% 12.28 US$22,239